Investor Presentaiton
10
Commercial execution and innovation
Diabetes care
Region China remains a key strategic opportunity
Region China is a large market with
~140 million people living with diabetes
.
Outcome of VBP insulin in China
Price cuts ~40-50% as a result of VBP
Keeps -50% of own brand volume in scope
22%
23%
•
Resource re-allocation towards growth
products
78%
77%
IO sales
IO patients
Region China
Rest of IO
TRESIBA
insulin degludec [rDNA origin] injection
NovoMix®
(biphasic insulin aspart)
human insulin MixtardⓇ30
Levemir®
(insulin detemir)
biphasic insulin
Novo Rapid
(insulin aspart)
RYZODEG
70% insulin degludec and 30% insulin aspart
[rDNA origin] injection
Xultophy
insulin degludec/liraglutide
[rDNA origin] injection
OZEMPİC
semaglutide injection
Note: IQVIA value in China only covers -60% of the market
Region China includes Mainland China, Taiwan and Hong Kong; VBP: Volume-based procurement; OAD: Oral anti-diabetes; IO: International Operations
Source: IQVIA, MAT value December 2021
Opportunities and strategic priorities
跟
Large growing diabetes market
Market of 25 bDKK mainly
consisting of OAD and insulin
Diabetes market growth of ~7%
DO
•
Bring innovation faster to market
Diabetes: RybelsusⓇ and
ONWARDS programme for Icodec
Rare disease: Across portfolio
Treat more patients
Expand patient base across new
insulins and GLP-1s
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation